PA
RAPP

Perceptive Advisors’s Rapport Therapeutics RAPP Stock Holding History

Perceptive Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32.2M Buy
773,342
+99,419
+15% +$3.65M 0.48% 44
2026
Q1 		$21.1M Hold
673,923
– – 0.41% 52
2025
Q4 		$20.4M Buy
673,923
+270,000
+67% +$7.47M 0.36% 62
2025
Q3 		$12M Buy
+403,923
New +$7.21M 0.35% 52
2025
Q1 		– Sell
-311,551
Closed -$5.53M – 110
2024
Q4 		$5.53M Sell
311,551
-436,632
-58% -$9.68M 0.15% 70
2024
Q3 		$15.3M Hold
748,183
– – 0.32% 62
2024
Q2 		$17.4M Buy
+748,183
New +$17.3M 0.42% 57

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Perceptive Advisors's RAPP Position: Q2 2026 in Review

Perceptive Advisors increased its Rapport Therapeutics (RAPP) stake by 15% in Q2 2026, buying an estimated $3.65M and bringing the position to 773,342 shares worth $32.2M. The position accounts for 0.48% of the portfolio, ranked #44.

Perceptive Advisors first reported a position in RAPP in Q2 2024 and has held it in 7 quarters since. 161 funds tracked by Wall St. Rank hold RAPP as of Q2 2026.

  • Perceptive Advisors held 773,342 shares of Rapport Therapeutics worth $32.2M as of Q2 2026.
  • Perceptive Advisors bought 99,419 Rapport Therapeutics shares in Q2 2026, an estimated $3.65M.
  • Rapport Therapeutics made up 0.48% of Perceptive Advisors's portfolio in Q2 2026, its #44 holding.
  • Perceptive Advisors first reported a position in Rapport Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • 161 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q2 2026.

Based on Perceptive Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.